Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

被引：0
|
作者：
Ashleigh McGirr
Shehzad M. Iqbal
Jan Olbrecht
Lijoy Varghese
机构：
[1] GSK,
[2] GSK,undefined
[3] GSK,undefined
来源：
Infectious Diseases and Therapy | 2018年 / 7卷
关键词：
Canada; Cost-effectiveness; Invasive pneumococcal disease; PCV-13; PHiD-CV; Pneumococcal conjugate vaccines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：535 / 538
页数：3
相关论文
共 21 条
  • [1] Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018
    McGirr, Ashleigh
    Iqbal, Shehzad M.
    Olbrecht, Jan
    Varghese, Lijoy
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 535 - 538
  • [2] Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada"
    Wilson, Michele R.
    Wasserman, Matt
    Jadavji, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie R.
    McDade, Cheryl
    Sings, Heather L.
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 539 - 543
  • [3] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Michele Wilson
    Matt Wasserman
    Taj Jadavi
    Maarten Postma
    Marie-Claude Breton
    Francois Peloquin
    Stephanie Earnshaw
    Cheryl McDade
    Heather Sings
    Raymond Farkouh
    Infectious Diseases and Therapy, 2018, 7 : 353 - 371
  • [4] Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”
    Michele R. Wilson
    Matt Wasserman
    Taj Jadavji
    Maarten Postma
    Marie-Claude Breton
    Francois Peloquin
    Stephanie R. Earnshaw
    Cheryl McDade
    Heather L. Sings
    Raymond Farkouh
    Infectious Diseases and Therapy, 2018, 7 : 539 - 543
  • [5] Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
    Wilson, Michele
    Wasserman, Matt
    Jadavi, Taj
    Postma, Maarten
    Breton, Marie-Claude
    Peloquin, Francois
    Earnshaw, Stephanie
    McDade, Cheryl
    Sings, Heather
    Farkouh, Raymond
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (03) : 353 - 371
  • [6] COST-EFFECTIVENESS OF 13-VALENT AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION RELATIVE TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA
    Whillans, F.
    Kwan, H.
    Strutton, D. R.
    Earnshaw, S. R.
    Farkouh, R.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [7] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
    Ansaldi, Filippo
    Pugh, Sarah
    Amicizia, Daniela
    Di Virgilio, Roberto
    Trucchi, Cecilia
    Orsi, Andrea
    Zollo, Alessandro
    Icardi, Giancarlo
    PATHOGENS, 2020, 9 (02):
  • [8] Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'"
    Wasserman, Matt
    Gabriela Palacios, Maria
    Gabriela Grajales, Ana
    Wilson, Michele
    McDade, Cheryl
    Farkouh, Raymond
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 572 - 574
  • [9] CLINICAL AND ECONOMIC IMPACT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN SINGAPORE AND HONG KONG
    Rinaldi, F.
    Hwang, S.
    Strutton, D.
    Earnshaw, S.
    Farkouh, R.
    VALUE IN HEALTH, 2010, 13 (03) : A191 - A192
  • [10] Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico"
    Gomez, Jorge A.
    Guzman Holst, Adriana
    Nieto, Javier
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 570 - 571
123